Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Astounding Treehouses All over the Planet - 2People with depression can treat themselves at home with new device
- 3Becoming Familiar with an Unknown dialect: My Language Learning Excursion
- 4Global measles cases drop 71% in 24 years as vaccination coverage improves, WHO says
- 5What were the little white pills found in Tiger Woods's pocket at the scene of his crash? What to know about hydrocodone.
- The Effect of Online Organizations on Society: Beating the Difficulties
- April’s full pink moon will rise in the night sky this week
- NASA’s Artemis II mission will take an astronaut crew around the Moon – a space policy expert describes the long road to launch
- EU waters down plans to end new petrol and diesel car sales by 2035
- April full moon 2026 dazzles as 'Pink Moon' lights up skies worldwide (photos)
- Some are walking out. Some are shouting. Some are oblivious. How kids are reacting to THAT 'Wicked: For Good' scene
- Faulty glucose monitors linked to 7 deaths and more than 700 injuries, FDA warns
- 10 Demonstrated Tips to Dominate Video Altering on Your Cell phone in 2023
- 'Harmonious' meeting between Merz, Lula despite Belém controversy
